Identifying cancers sensitive to treatment with inhibitors...

Details Identifying cancers sensitive to treatment with inhibitors... Identifying cancers sensitive to treatment with inhibitors...

2009-01-27

2009-06-09

Horlick, Kenneth R. (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

07544476

ABSTRACT:
The disclosure provides a method for identifying cancer tissue sensitive to treatment with an inhibitor of Notch receptor activation. The method comprises determining the level of HeyL gene expression in a sample derived from the cancer tissue, wherein an elevated level of HeyL gene expression alone in the sample indicates sensitivity to the cancer tissue to treatment with an inhibitor of Notch receptor activation.

REFERENCES:
patent: WO-2006/047878 (2006-05-01), None
patent: WO-2006/092062 (2006-09-01), None
patent: WO-2007/136856 (2007-11-01), None
Iso et al. “HES and HERP Families: Multiple Effectors of the Notch Signaling Pathway” (2003)J. Cellular Physiol.194:237-255.
Leong et al. “Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin” (2007)J. Experimental Med.204:2935-2948.
Parker et al. “Alterations in Vascular Gene Expression in Invasive Breast Carcinoma” (2004)Cancer Research64:7857-7866.

Affiliated with

Also associated with

Rating

Identifying cancers sensitive to treatment with inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identifying cancers sensitive to treatment with inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identifying cancers sensitive to treatment with inhibitors... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4098332